A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-708 in Healthy Subjects

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple ascending doses of VX-708 in healthy participants

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Key Inclusion Criteria:

• Male and female of non-childbearing potential are eligible
• Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m^2)
• A total body weight greater than (>) 50 kg

Key Exclusion Criteria:

• History of febrile illness or other acute illness within 14 days before the first dose of study drug

• History of cardiac dysrhythmias

• Part A Cohorts with Midazolam DDI Evaluation (Cohort A4) Only

  • Hypersensitivity to midazolam or benzodiazepines

• Part A Cohorts with CSF Sampling (Cohorts A2 and A3) Only

  • Hypersensitivity to local anesthetic for lumbar puncture
  • History of conditions leading to increased intracranial pressure (e.g., brain tumor, idiopathic intracranial hypertension, venous sinus thrombosis)

• Part B Only

  • Hypersensitivity to itraconazole

Other protocol defined Inclusion/Exclusion criteria may apply.